Company news

ACADIA Pharmaceuticals Inc. news in 2022

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2022, newest first.

View company

Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

December 20, 2022

Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 1, 2022

Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic

October 26, 2022

Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

October 19, 2022

Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors

October 12, 2022

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

October 3, 2022

Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

September 11, 2022

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 7, 2022

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

August 3, 2022

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

July 24, 2022

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

July 17, 2022

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

June 16, 2022

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

May 3, 2022

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022

May 1, 2022

Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022

April 20, 2022

Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain

April 17, 2022

Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)

March 21, 2022

Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022

March 9, 2022

Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

March 8, 2022

Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

March 2, 2022

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

February 15, 2022

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

February 13, 2022

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

February 10, 2022

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

January 9, 2022

Calls in 2022

Decks in 2022